changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
An open-label, prospective, multicenter, randomized, Phase III clinical trial evaluating yttrium-90 transarterial radioembolization (TheraSphere®) versus the standard of care (sorafenib) for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT).29,30
Standard-of-care therapy: sorafenib
To assess efficacy and safety of TheraSphere® in comparison to sorafenib therapy in the treatment of patients with PVT associated with unresectable HCC.
Primary: Overall survival)
Secondary:Time to progression, time to worsening portal vein thrombosis, response rate, time to symptomatic progression, quality of life (FACT-hep), safety
Please visit the THERASPHERE TRIALS WEBSITE for more details
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com